CASE REPORT
Septic shock syndrome associated with generalized vasculitis
Online publication date: 2012-06-27
Reumatologia 2012;50(3):243-249
KEYWORDS
ABSTRACT
Toxic shock syndrome is a severe systemic inflammatory response syndrome caused by streptococcal or staphylococcal infection, characterized by sudden onset of high fever, skin rash and the symptoms of multiple organ dysfunction leading to shock. Diagnosis is based on clinical symptoms and positive blood and/or focus of infection cultures (Table I, II). Treatment includes antibiotics, immunoglobulins, and intensive therapy. Patients with toxic shock syndrome require treatment in an intensive care department.
The paper presents the clinical symptoms (Fig. 1) and the therapeutic and diagnostic difficulties associated with toxic shock syndrome in the example of a clinical case of a 3-year-old boy diagnosed with this syndrome.
The paper presents the clinical symptoms (Fig. 1) and the therapeutic and diagnostic difficulties associated with toxic shock syndrome in the example of a clinical case of a 3-year-old boy diagnosed with this syndrome.
REFERENCES (17)
1.
Todd J, Fishaut M, Kapral F. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet 1978; 2: 1116-1118.
2.
Shands KN, Schmid GP, Dan BB, et al. Toxic shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med 1980; 303: 1436-1442.
3.
Berk DR, Bayliss SJ. MRSA, staphylococcal scalded skin syndrome, and other cutaneous bacterial ermergencies. Ped Ann 2010; 39: 627-633.
4.
Wissental AM, Todd JK. Toxic shock Syndrome in Children Aged 10 Years or Less. Pediatrics 2006; 118: 2450-2460.
5.
Davis JP, Chesney PJ, Wand PJ, LaVenture M. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention. N Engl J Med 1980; 303: 1429-1435.
6.
Chesney PJ, Davis JP, Purdy WK, et al. Clinical manifestations of toxic shock syndrome. JAMA 1981; 246: 741-748.
8.
Davies HD, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N Engl J Med 1996; 335: 547-554.
9.
Rodríguez-Nun~ez A, Dosil-Gallardo S, Jordan I. Clinical characteristics of children with group A streptococcal toxic shock syndrome admitted to pediatric intensive care units. Streptococcal Toxic Shock Syndrome collaborative group of Spanish Society of Pediatric Intensive Care. Eur J Pediatr 2011; 170: 639-644.
10.
Schlievert PM. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J Allergy Clin Immunol 2001; 108 (4 Suppl): S107-S110.
11.
The Canadian Streptococcal Study Group. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome – a comparative observational study. Clin Infect Dis 1999; 28: 800-807.
12.
Barry W, Hudgins L, Donta ST, et al. Intravenous immunoglobulin therapy for toxic-shock syndrome. JAMA 192; 267: 3315-3317.
13.
Leung DY, Meissner HC, Fulton DR, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet 1993; 342: 1385-1388.
14.
Russell NE, Pachorek RE. Clindamycin in the treatment of streptococcal and staphylococcal toxic shock syndromes. Ann Pharmacother 2000; 34: 936-939.
15.
Vinson AE, Dufort EM, Willis MD, et al. Drug rash, eosinophilia, and systemic symptoms syndrome: Two pediatric cases demonstrating the range of severity in presentation – a case of vancomycin-induced drug hypersensitivity mimicking toic shock syndrome and a milder case induced by minocycline. Pediatr Crit Care Med 2010; 11: 38-43.
16.
Szenborn L. Zastosowanie preparatów immunoglobulin w leczeniu chorób zakaźnych. Pol Merk Lek 2011; 30: 441-446.
17.
Szczypa K, Hryniewicz W. Streptococcus pyogenes – inwazyjna natura patogenu. Nowa Klinika 2006; 13: 722-725.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
